p53, a target of estrogen receptor (ER) α, modulates DNA damage-induced growth suppression in ER-positive breast cancer cells

Journal of Biological Chemistry

Volumn 287, Issue 36, 2012, Pages 30117-30127

  Berger, Crystal E ^a   Qian, Yingjuan ^a   Liu, Gang ^b   Chen, Hongwu ^c   Chen, Xinbin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-ESTROGENS; BREAST CANCER; BREAST CANCER CELLS; CELL-CYCLE ARREST; DNA DAMAGE RESPONSE; DNA REPAIR; DOWNSTREAM TARGET; ECTOPIC EXPRESSIONS; ESTROGEN RECEPTOR; ESTROGEN RESPONSE ELEMENTS; FEED-BACK LOOP; GENOTOXIC STRESS; GROWTH SUPPRESSIONS; HUMAN CANCER; INVASIVENESS; MUTATED GENES; P53 FUNCTION; PATIENT PROGNOSIS; TAMOXIFEN; TARGET GENES; TUMOR GROWTH; TUMOR SUPPRESSORS;

CELL DEATH; DIAGNOSIS; DNA; GENES; PATIENT TREATMENT; TRANSCRIPTION; TUMORS;

DISEASES;

CELL DNA; ESTROGEN RECEPTOR ALPHA; PROTEIN P53;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN RESPONSIVE ELEMENT; FEEDBACK SYSTEM; GENE; GENE EXPRESSION; GENE TARGETING; MDM2 GENE; P21 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN DNA BINDING; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DNA, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865767406     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.367326     Document Type: Article

References (69)

1. Mosselman, S., Polman, J., and Dijkema, R. (1996) ERβ: identification and characterization of a novel human estrogen receptor. FEBS Lett. 392, 49-53
2. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., and Gustafsson, J. A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870
3. Stanford, J. L., Szklo, M., and Brinton, L. A. (1986) Estrogen receptors and breast cancer. Epidemiol. Rev. 8, 42-59
4. Leygue, E., Dotzlaw, H., Watson, P. H., and Murphy, L. C. (1998) Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res. 58, 3197-3201
5. Lazennec, G., Bresson, D., Lucas, A., Chauveau, C., and Vignon, F. (2001) ERβ inhibits proliferation and invasion of breast cancer cells. Endocrinology 142, 4120-4130
6. Allegra, J. C., and Lippman, M. E. (1980) Estrogen receptor status and the disease-free interval in breast cancer. Recent Results Cancer Res. 71, 20-25
7. Ottaviano, Y. L., Issa, J. P., Parl, F. F., Smith, H. S., Baylin, S. B., and Davidson, N. E. (1994) Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54, 2552-2555
8. Parl, F. F., Schmidt, B. P., Dupont, W. D., and Wagner, R. K. (1984) Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary node metastasis, and histopathologic grading. Cancer 54, 2237-2242
9. Vousden, K. H., and Prives, C. (2009) Blinded by the light: the growing complexity of p53. Cell 137, 413-431
10. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825
11. Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245
12. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. (1991) p53 mutations in human cancers. Science 253, 49-53
13. Pharoah, P. D., Day, N. E., and Caldas, C. (1999) Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br. J. Cancer 80, 1968-1973
14. Angeloni, S. V., Martin, M. B., Garcia-Morales, P., Castro-Galache, M. D., Ferragut, J. A., and Saceda, M. (2004) Regulation of estrogen receptor-α expression by the tumor suppressor gene p53 in MCF-7 cells. J. Endocrinol. 180, 497-504
15. Shirley, S. H., Rundhaug, J. E., Tian, J., Cullinan-Ammann, N., Lambertz, I., Conti, C. J., and Fuchs-Young, R. (2009) Transcriptional regulation of estrogen receptor α by p53 in human breast cancer cells. Cancer Res. 69, 3405-3414
16. Yu, C. L., Driggers, P., Barrera-Hernandez, G., Nunez, S. B., Segars, J. H., and Cheng, S. (1997) The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem. Biophys. Res. Commun. 239, 617-620
17. Sayeed, A., Konduri, S. D., Liu, W., Bansal, S., Li, F., and Das, G. M. (2007) Estrogen receptor α inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 67, 7746-7755
18. Qin, C., Nguyen, T., Stewart, J., Samudio, I., Burghardt, R., and Safe, S. (2002) Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated by calmodulin kinase IV-dependent activation of a nuclear factor κB/CCAAT-binding transcription factor-1 complex. Mol. Endocrinol. 16, 1793-1809
19. Liu, G., Xia, T., and Chen, X. (2003) The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J. Biol. Chem. 278, 17557-17565
20. Yan, W., and Chen, X. (2006) GPX2, a direct target of p63, inhibits oxidative stress-induced apoptosis in a p53-dependent manner. J. Biol. Chem. 281, 7856-7862
21. Johansen, F. E., and Prywes, R. (1994) Two pathways for serum regulation of the c-fos serum response element require specific sequence elements and a minimal domain of serum response factor. Mol. Cell. Biol. 14, 5920-5928
22. Harms, K. L., and Chen, X. (2007) Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res. 67, 3145-3152
23. Liu, G., and Chen, X. (2005) The C-terminal sterile α motif and the extreme C terminus regulate the transcriptional activity of the α isoform of p73. J. Biol. Chem. 280, 20111-20119
24. Qian, Y., Jung, Y. S., and Chen, X. (2011) ΔNp63, a target of DEC1 and histone deacetylase 2, modulates the efficacy of histone deacetylase inhibitors in growth suppression and keratinocyte differentiation. J. Biol. Chem. 286, 12033-12041
25. Qian, Y., and Chen, X. (2008) ID1, inhibitor of differentiation/DNA binding, is an effector of the p53-dependent DNA damage response pathway. J. Biol. Chem. 283, 22410-22416
26. Gretarsdottir, S., Tryggvadottir, L., Jonasson, J. G., Sigurdsson, H., Olafsdottir, K., Agnarsson, B. A., Ogmundsdottir, H., and Eyfjörd, J. E. (1996) TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br. J. Cancer 74, 555-561
27. Fernández-Cuesta, L., Anaganti, S., Hainaut, P., and Olivier, M. (2011) Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines. Breast Cancer Res. Treat. 125, 35-42
28. Holst, F., Stahl, P. R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K., Jänicke, F., Sauter, G., and Simon, R. (2007) Estrogen receptor α (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 39, 655-660
29. Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K., and Gewirtz, D. A. (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol. 45, 649-656
30. Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., Myklebost, O., Heimbrook, D. C., and Vassilev, L. T. (2006) Small-moleculeMDM2antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. U.S.A. 103, 1888-1893
31. Troester, M. A., Herschkowitz, J. I., Oh, D. S., He, X., Hoadley, K. A., Barbier, C. S., and Perou, C. M. (2006) Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 6, 276
32. Jakowlew, S. B., Breathnach, R., Jeltsch, J. M., Masiakowski, P., and Chambon, P. (1984) Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Res. 12, 2861-2878
33. Klein-Hitpass, L., Ryffel, G. U., Heitlinger, E., and Cato, A. C. (1988) A 13 bp palindrome is a functional estrogen responsive element and interacts specifically with estrogen receptor. Nucleic Acids Res. 16, 647-663
34. Driscoll, M. D., Sathya, G., Muyan, M., Klinge, C. M., Hilf, R., and Bambara, R. A. (1998) Sequence requirements for estrogen receptor binding to estrogen response elements. J. Biol. Chem. 273, 29321-29330
35. Carroll, J. S., Liu, X. S., Brodsky, A. S., Li, W., Meyer, C. A., Szary, A. J., Eeckhoute, J., Shao, W., Hestermann, E. V., Geistlinger, T. R., Fox, E. A., Silver, P. A., and Brown, M. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122, 33-43
36. Rosenbloom, K. R., Dreszer, T. R., Pheasant, M., Barber, G. P., Meyer, L. R., Pohl, A., Raney, B. J., Wang, T., Hinrichs, A. S., Zweig, A. S., Fujita, P. A., Learned, K., Rhead, B., Smith, K. E., Kuhn, R. M., Karolchik, D., Haussler, D., and Kent, W. J. (2010) ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res. 38, D620-D625
37. Brown, A. M., Jeltsch, J. M., Roberts, M., and Chambon, P. (1984) Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc. Natl. Acad. Sci. U.S.A. 81, 6344-6348
38. Parker, M. G., Arbuckle, N., Dauvois, S., Danielian, P., and White, R. (1993) Structure and function of the estrogen receptor. Ann. N.Y. Acad. Sci. 684, 119-126
39. Huang, J., Li, X., Maguire, C. A., Hilf, R., Bambara, R. A., and Muyan, M. (2005) Binding of estrogen receptor α to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Mol. Endocrinol. 19, 2696-2712
40. Shiozawa, T., Miyamoto, T., Kashima, H., Nakayama, K., Nikaido, T., and Konishi, I. (2004) Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene 23, 8603-8610
41. Liu, G., and Chen, X. (2006) DNA Polymerase η, the product of the xeroderma pigmentosum variant gene and a target of p53, modulates theDNA damage checkpoint and p53 activation. Mol. Cell. Biol. 26, 1398-1413
42. Tan, M., Wang, Y., Guan, K., and Sun, Y. (2000) PTGF-β, a type β transforming growth factor (TGF-β) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-β signaling pathway.. Proc. Natl. Acad. Sci. U.S.A. 97, 109-114
43. Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., and Vogelstein, B. (2001) PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7, 673-682
44. Nakano, K., and Vousden, K. H. (2001) PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694
45. Qian, Y., Jung, Y. S., and Chen, X. (2012) Differentiated embryo-chondrocyte expressed gene 1 regulates p53-dependent cell survival versus cell death through macrophage inhibitory cytokine-1. Proc. Natl. Acad. Sci. U.S.A. 109, 11300-11305
46. Sluyser, M., and Van Nie, R. (1974) Estrogen receptor content and hormone-responsive growth of mouse mammary tumors. Cancer Res. 34, 3253-3257
47. Ivshina, A. V., George, J., Senko, O., Mow, B., Putti, T. C., Smeds, J., Lindahl, T., Pawitan, Y., Hall, P., Nordgren, H., Wong, J. E., Liu, E. T., Bergh, J., Kuznetsov, V. A., and Miller, L. D. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66, 10292-10301
48. Kao, K. J., Chang, K. M., Hsu, H. C., and Huang, A. (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11, 143
49. Aitken, S. C., and Lippman, M. E. (1985) Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res. 45, 1611-1620
50. Gasco, M., Shami, S., and Crook, T. (2002) The p53 pathway in breast cancer. Breast Cancer Res. 4, 70-76
51. Agrawal, A., Yang, J., Murphy, R. F., and Agrawal, D. K. (2006) Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer. Exp. Mol. Pathol. 81, 115-122
52. Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B. A., Osin, P., Farrell, P. J., Yulug, I., Evans, A., Ozcelik, T., Gasco, M., and Crook, T. (2002) Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene 21, 1316-1324
53. Gentile, M., Ahnström, M., Schön, F., and Wingren, S. (2001) Candidate tumour suppressor genes at 11q23-q24 in breast cancer: evidence of alterations in PIG8, a gene involved in p53-induced apoptosis. Oncogene 20, 7753-7760
54. Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K., Chan, T. A., Hermeking, H., Marks, J. R., Lambers, A. R., Futreal, P. A., Stampfer, M. R., and Sukumar, S. (2000) High frequency of hypermethylation at the 14-3-3σ locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 97, 6049-6054
55. Raman, V., Martensen, S. A., Reisman, D., Evron, E., Odenwald, W. F., Jaffee, E., Marks, J., and Sukumar, S. (2000) Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405, 974-978
56. Kirch, H. C., Flaswinkel, S., Rumpf, H., Brockmann, D., and Esche, H. (1999) Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-κB and Myc/Max. Oncogene 18, 2728-2738
57. Gu, G., Barone, I., Gelsomino, L., Giordano, C., Bonofiglio, D., Statti, G., Menichini, F., Catalano, S., and Andò, S. (2012) Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERα/Sp1-mediated p53 activation. J. Cell. Physiol. 227, 3363-3372
58. Dauvois, S., White, R., and Parker, M. G. (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 106, 1377-1388
59. Howell, A., Osborne, C. K., Morris, C., and Wakeling, A. E. (2000) ICI 182,780 (Faslodex™). Cancer 89, 817-825
60. Barkhem, T., Nilsson, S., and Gustafsson, J. A. (2004) Molecular mechanisms, physiological consequences and pharmacological implications of estrogen receptor action. Am. J. Pharmacogenomics 4, 19-28
61. Ariazi, E. A., Ariazi, J. L., Cordera, F., and Jordan, V. C. (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr. Top. Med. Chem. 6, 181-202
62. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., Cutter, D., Darby, S., McGale, P., Taylor, C., Wang, Y. C., Bergh, J., Di Leo, A., Albain, K., Swain, S., Piccart, M., and Pritchard, K. (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379, 432-444
63. Hubay, C. A., Pearson, O. H., Manni, A., Gordon, N. H., and McGuire, W. L. (1985) Adjuvant endocrine therapy, cytotoxic chemotherapy and immunotherapy in stage II breast cancer: 6-year result. J. Steroid Biochem. 23, 1147-1150
64. Sasa, M., Kondo, K., Komaki, K., Morimoto, T., and Monden, Y. (1994) p53 alteration correlates with negative ER, negative PgR, and high histologic grade in breast cancer. J. Surg. Oncol. 56, 46-50
65. Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P., and Olivier, M. (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157-2165
66. Velculescu, V. E., and El-Deiry, W. S. (1996) Biological and clinical importance of the p53 tumor suppressor gene. Clin. Chem. 42, 858-868
67. Thompson, A. M., and Lane, D. P. (2009) p53 transcriptional pathways in breast cancer: the good, the bad and the complex. J. Pathol. 220, 401-403
68. Harvey, J. M., Clark, G. M., Osborne, C. K., and Allred, D. C. (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474-1781
69. Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K., and Isola, J. (1996) Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol. 14, 2584-2589